168 related articles for article (PubMed ID: 27768280)
1. Chemical Proteomics and Structural Biology Define EPHA2 Inhibition by Clinical Kinase Drugs.
Heinzlmeir S; Kudlinzki D; Sreeramulu S; Klaeger S; Gande SL; Linhard V; Wilhelm M; Qiao H; Helm D; Ruprecht B; Saxena K; Médard G; Schwalbe H; Kuster B
ACS Chem Biol; 2016 Dec; 11(12):3400-3411. PubMed ID: 27768280
[TBL] [Abstract][Full Text] [Related]
2. Chemoproteomics-Aided Medicinal Chemistry for the Discovery of EPHA2 Inhibitors.
Heinzlmeir S; Lohse J; Treiber T; Kudlinzki D; Linhard V; Gande SL; Sreeramulu S; Saxena K; Liu X; Wilhelm M; Schwalbe H; Kuster B; Médard G
ChemMedChem; 2017 Jun; 12(12):999-1011. PubMed ID: 28544567
[TBL] [Abstract][Full Text] [Related]
3. Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction.
Pala D; Castelli R; Incerti M; Russo S; Tognolini M; Giorgio C; Hassan-Mohamed I; Zanotti I; Vacondio F; Rivara S; Mor M; Lodola A
J Chem Inf Model; 2014 Oct; 54(10):2621-6. PubMed ID: 25289483
[TBL] [Abstract][Full Text] [Related]
4. 4-Substituted quinazoline derivatives as novel EphA2 receptor tyrosine kinase inhibitors.
Lim CJ; Oh KS; Ha JD; Lee JH; Seo HW; Chae CH; Kim DG; Lee MJ; Lee BH
Bioorg Med Chem Lett; 2014 Sep; 24(17):4080-3. PubMed ID: 25124116
[TBL] [Abstract][Full Text] [Related]
5. Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists.
Callegari D; Pala D; Scalvini L; Tognolini M; Incerti M; Rivara S; Mor M; Lodola A
Molecules; 2015 Sep; 20(9):17132-51. PubMed ID: 26393553
[TBL] [Abstract][Full Text] [Related]
6. Identification of potent pan-ephrin receptor kinase inhibitors using DNA-encoded chemistry technology.
Madasu C; Liao Z; Parks SE; Sharma KL; Bohren KM; Ye Q; Li F; Palaniappan M; Tan Z; Yuan F; Creighton CJ; Tang S; Masand RP; Guan X; Young DW; Monsivais D; Matzuk MM
Proc Natl Acad Sci U S A; 2024 May; 121(19):e2322934121. PubMed ID: 38701119
[TBL] [Abstract][Full Text] [Related]
7. Engineering nanomolar peptide ligands that differentially modulate EphA2 receptor signaling.
Gomez-Soler M; Petersen Gehring M; Lechtenberg BC; Zapata-Mercado E; Hristova K; Pasquale EB
J Biol Chem; 2019 May; 294(22):8791-8805. PubMed ID: 31015204
[TBL] [Abstract][Full Text] [Related]
8. Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis.
Giorgio C; Russo S; Incerti M; Bugatti A; Vacondio F; Barocelli E; Mor M; Pala D; Hassan-Mohamed I; Gioiello A; Rusnati M; Lodola A; Tognolini M
Biochem Pharmacol; 2016 Jan; 99():18-30. PubMed ID: 26462575
[TBL] [Abstract][Full Text] [Related]
9. Chemical Proteomics Uncovers EPHA2 as a Mechanism of Acquired Resistance to Small Molecule EGFR Kinase Inhibition.
Koch H; Busto ME; Kramer K; Médard G; Kuster B
J Proteome Res; 2015 Jun; 14(6):2617-25. PubMed ID: 25963923
[TBL] [Abstract][Full Text] [Related]
10. Expression and Purification of EPHA2 Tyrosine Kinase Domain for Crystallographic and NMR Studies.
Gande SL; Saxena K; Sreeramulu S; Linhard V; Kudlinzki D; Heinzlmeir S; Reichert AJ; Skerra A; Kuster B; Schwalbe H
Chembiochem; 2016 Dec; 17(23):2257-2263. PubMed ID: 27685543
[TBL] [Abstract][Full Text] [Related]
11. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
Verkhivker GM
Proteins; 2007 Mar; 66(4):912-29. PubMed ID: 17173284
[TBL] [Abstract][Full Text] [Related]
12. The Sam-Sam interaction between Ship2 and the EphA2 receptor: design and analysis of peptide inhibitors.
Mercurio FA; Di Natale C; Pirone L; Iannitti R; Marasco D; Pedone EM; Palumbo R; Leone M
Sci Rep; 2017 Dec; 7(1):17474. PubMed ID: 29234063
[TBL] [Abstract][Full Text] [Related]
13. Structural investigation of a C-terminal EphA2 receptor mutant: Does mutation affect the structure and interaction properties of the Sam domain?
Mercurio FA; Costantini S; Di Natale C; Pirone L; Guariniello S; Scognamiglio PL; Marasco D; Pedone EM; Leone M
Biochim Biophys Acta Proteins Proteom; 2017 Sep; 1865(9):1095-1104. PubMed ID: 28602916
[TBL] [Abstract][Full Text] [Related]
14. Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype.
Paraiso KH; Das Thakur M; Fang B; Koomen JM; Fedorenko IV; John JK; Tsao H; Flaherty KT; Sondak VK; Messina JL; Pasquale EB; Villagra A; Rao UN; Kirkwood JM; Meier F; Sloot S; Gibney GT; Stuart D; Tawbi H; Smalley KS
Cancer Discov; 2015 Mar; 5(3):264-73. PubMed ID: 25542447
[TBL] [Abstract][Full Text] [Related]
15. Target hopping as a useful tool for the identification of novel EphA2 protein-protein antagonists.
Tognolini M; Incerti M; Pala D; Russo S; Castelli R; Hassan-Mohamed I; Giorgio C; Lodola A
ChemMedChem; 2014 Jan; 9(1):67-72. PubMed ID: 24115725
[TBL] [Abstract][Full Text] [Related]
16. The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells.
Giorgio C; Mena P; Del Rio D; Brighenti F; Barocelli E; Hassan-Mohamed I; Callegari D; Lodola A; Tognolini M
Mol Nutr Food Res; 2015 Nov; 59(11):2155-67. PubMed ID: 26307544
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and structure-activity relationships of amino acid conjugates of cholanic acid as antagonists of the EphA2 receptor.
Russo S; Incerti M; Tognolini M; Castelli R; Pala D; Hassan-Mohamed I; Giorgio C; De Franco F; Gioiello A; Vicini P; Barocelli E; Rivara S; Mor M; Lodola A
Molecules; 2013 Oct; 18(10):13043-60. PubMed ID: 24152675
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship analysis of peptides targeting the EphA2 receptor.
Mitra S; Duggineni S; Koolpe M; Zhu X; Huang Z; Pasquale EB
Biochemistry; 2010 Aug; 49(31):6687-95. PubMed ID: 20677833
[TBL] [Abstract][Full Text] [Related]
19. A computational and laboratory approach for the investigation of interactions of peptide conjugated natural terpenes with EpHA2 receptor.
Goncalves BG; Banerjee IA
J Mol Model; 2023 Jun; 29(7):204. PubMed ID: 37291458
[TBL] [Abstract][Full Text] [Related]
20. Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro-survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor.
Ståhl S; Branca RM; Efazat G; Ruzzene M; Zhivotovsky B; Lewensohn R; Viktorsson K; Lehtiö J
J Proteome Res; 2011 May; 10(5):2566-78. PubMed ID: 21413766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
